pharmaphorum3d
Novartis' bid to extend Kymriah into earlier use hits a roadblock
Novartis' CAR-T therapy Kymriah racked up back-to-back approvals in acute lymphoblastic leukaemia and large B-cell lymphoma a few years ago, but hasn't added to its label since.
pharmaphorum3d
Novartis and FDA hail 'historic' Kymriah, first ever approved CAR-T
Novartis is also establishing a network of certified treatment centres throughout the country which will be fully trained on the use of Kymriah and appropriate patient care. Gilead in the picture ...
Miltenyi Biotec’s ZAMTO Cell, claimed to be India's first dual-target CAR-T cancer therapy, expected by 2026
The company said that ZAMTO Cell is designed to target both CD19 and CD20, which could improve treatment efficacy.
Finanznachrichten3d
CAR T-Cell Therapy Market Size To Reach 27.5 Billion by 2033 Owing to Rising Awareness and Favourable Reimbursement Policies Says Astute Analytica
In 2023, Yescarta generated USD 1.4 billion in sales, with over 1,300 patients treated, while Kymriah achieved USD ... including Novartis AG, Bluebird Bio, Inc., Cellectis, Bristol-Myers Squibb ...
Investing2d
Oxford BioMedica PLC (OXB)
Following the commercial launch in 2017 of partner Novartis’s CAR-T Kymriah (in r/r paediatric ALL), Oxford BioMedica plc ...
London South East4d
Hemogenyx Share Chat (HEMO)
For approved therapies like Kymriah (Novartis) or Yescarta (Gilead/Kite), production costs are estimated to range between $50,000 and $150,000 per treatment, though these figures reflect ...